The number of patients treated with anticoagulants has significantly increased over the past decade, largely owing to the introduction of direct oral anticoagulants (DOACs). Currently, more than 6 million people nationwide are taking anticoagulants; these include patients receiving care through the Veterans Health Administration.
However, the growing use of oral anticoagulants has been accompanied by a rise in anticoagulant-related bleeding incidents. Dr Geoffrey Barnes from the University of Michigan discusses strategies to assess and manage bleeding events, and he reviews the most current recommendations on the appropriate selection and use of anticoagulation reversal agents.
Dr Barnes also underscores the importance of monitoring for thromboembolic complications in patients treated for life-threatening bleeding to prevent post-bleed thromboembolic events.
--
Associate Professor, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Pfizer; Bristol-Myers Squibb; Janssen; Bayer; AstraZeneca; Sanofi; Anthos; Abbott Vascular; Boston Scientific
Received research grant from: Boston Scientific